SERUM LEVELS OF INFLIXIMAB AND ADALIMUMAB BIOSIMILARS CAN BE MEASURED EQUIVALENTLY TO ORIGINATOR DRUGS BY QUANTUM BLUE RAPID TESTING AS TOOL FOR THERAPEUTIC DRUG MONITORING

Florian Frei ¹ Leslie Anchling ¹ Clara Moniz ¹ Thomas Schuster ¹
¹ BÜHLMANN Laboratories AG, Schönenbuch, Switzerland

Session
IBD (Posters)

Conference
UEG Week Virtual 2021

Citation
United European Gastroenterology Journal 2021; 9 (Supplement 8)

Do you need help setting up your myUEG account?
Contact us at [email protected]

Social Sharing